LOS ANGELES, March 20, 2023 (GLOBE NEWSWIRE) — The law office of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders in the following public companies. Investors have until the deadlines listed below to file a lead plaintiff filing.

Investors who experience losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email at fcruz@frankcruzlaw.com.

Y-mAbs Therapeutics, Inc. YMAB
Class Period: October 6, 2020 – October 28, 2022
Deadline for lead plaintiff: March 20, 2023

The Complaint filed in this Class Action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. In particular, Defendants have misrepresented to investors that, according to a series of meetings and other communications between the Company and the FDA, progress has been made that would be consistent with the FDA’s requirement to produce substantive proof of concept sufficient for approval of omurtamab adequate and well-controlled studies.

If you are a Y-mAbs shareholder who has suffered a loss, click Here participate.

Fate Therapeutics, Inc. FATE
Class Period: April 2, 2020 – January 5, 2023
Deadline for lead plaintiff: March 22, 2023

The Complaint filed in this Class Action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Janssen Collaboration Agreement was less viable than Fate represented to investors; (2) accordingly certain clinical programs, milestone payments and royalties payments related to the Janssen Collaboration Agreement…